Deal Ends Today·Save 35% annual plan
GLP-1 receptor agonistReviewed for 2026 plan year

Does Medica Cover Wegovy?

The verdict

Conditional on most plans

Medica covers Wegovy for weight loss on commercial/employer plans only where the employer has purchased the anti-obesity benefit; drug-level formulary detail is not publicly published and must be verified on the Medica drug-lookup tool. ACA/individual plans generally exclude it. Medicare Part D covers only the cardiovascular risk-reduction indication. Medicaid coverage varies across Medica's Upper Midwest states.

MedicareConditional
CommercialConditional
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Medica using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Medica drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Medica operates in six Upper Midwest states: Minnesota, Wisconsin, North Dakota, South Dakota, Iowa, and Nebraska.

    Medica.com plan information

  • Only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026, affecting Medica Medicaid members across its six-state footprint.

    KFF — Medicaid Coverage of and Spending on GLP-1s (January 2026)

  • Wegovy list price: $1,349/month in 2026; Novo Nordisk announced a cut to approximately $675/month effective January 1, 2027.

    Novo Nordisk press release, 2026

Plan types

Medicare vs. commercial coverage

Whether Medica covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Conditional

Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all Medica Medicare Advantage and standalone Part D plans. Medica Medicare plans can cover Wegovy for the cardiovascular risk-reduction indication (adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026, provides eligible beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — operating outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries.

Commercial / Employer

Group & marketplace plans

Conditional

Medica commercial and employer-sponsored plans cover Wegovy for weight loss only when the employer group has opted into anti-obesity drug coverage. Medica is a standalone regional plan — not a Blue affiliate — operating in Minnesota, Wisconsin, North Dakota, South Dakota, Iowa, and Nebraska. Medica does not publish drug-level Wegovy formulary detail in a publicly accessible document. Coverage, tier, and PA criteria vary by plan and must be verified using the Medica drug-lookup tool. Where coverage exists, prior authorization with standard BMI criteria (BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity) and a documented lifestyle program is expected. A 5% weight-loss renewal requirement is the industry standard for employer GLP-1 weight-loss coverage. If the employer carved out anti-obesity drugs, that is a benefit exclusion and is not appealable through PA. ACA/individual-market plans generally exclude Wegovy for weight loss. Medicaid coverage across Medica's states is state-dependent — only 13 states covered GLP-1s for obesity as of January 2026. NovoCare savings card ($25/month, max $100 per 28-day supply) is available to commercially insured members whose plan covers Wegovy; not available to Medicare or Medicaid beneficiaries.

Prior authorization

The 4 boxes you must tick to get approved

Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 4

Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period.

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Plan-specific cost-share — not publicly published for Medica Wegovy coverage. NovoCare savings card: commercially insured members with covered plans may pay as little as $25/month (up to $100 per 28-day supply). Confirm cost-share directly with Medica.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

Medicare GLP-1 Bridge: $50/month for eligible Medicare beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap.

Reduced copay through the assistance program, where eligible.

All figures are estimates and vary by plan, deductible phase, and pharmacy. Medica does not publish specific Wegovy cost-share — verify with your plan before starting treatment.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Ask your employer whether anti-obesity drugs are covered

    Before any formulary research or PA effort, ask HR or your benefits administrator whether weight-loss medications are included in your Medica plan. If anti-obesity drugs are excluded at the employer level, no PA will be approved. This step takes minutes and can prevent weeks of wasted effort.

  2. 2

    Search the Medica drug-lookup tool

    Visit medica.com and use the drug-lookup or formulary search with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm whether your specific plan covers it, the tier, and PA requirements. Medica does not publish a single centralized formulary — results depend on your specific plan contract.

  3. 3

    Work with your prescriber to submit prior authorization

    If your plan covers Wegovy, ask your prescriber to submit a PA. Document your BMI, any weight-related comorbidities, and your lifestyle program participation. Track weight-loss progress throughout treatment — renewal will typically require demonstrated weight loss at or above the 5% threshold.

If it's denied

Options if Medica won't cover Wegovy

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Medica Mounjaro coverage (T2D only)

If you have type 2 diabetes, Medica covers Mounjaro (tirzepatide) for that indication with prior authorization. Mounjaro is FDA-approved for type 2 diabetes, not weight loss. The FDA-approved weight-loss formulation of tirzepatide is Zepbound — do not confuse the two.

NovoCare self-pay program

NovoCare Pharmacy offers Wegovy at approximately $349/month without insurance. Introductory pricing applies for the first two dose levels through December 31, 2026. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.

Compounded semaglutide

Compounded semaglutide is available without insurance at a lower cost. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

Medica covers Wegovy for weight loss on commercial plans only where the employer has purchased anti-obesity drug coverage. Medica does not publish drug-level Wegovy formulary detail publicly — verify on the Medica drug-lookup tool at medica.com and confirm with your HR department. If the employer excluded weight-loss drugs, that is a benefit exclusion and cannot be overcome with a stronger PA.

Both Medica and BCBS of Minnesota are Minnesota-market plans with Wegovy formularies that are not publicly published in detail. The key difference is operator: Medica is a standalone regional plan, while BCBS of Minnesota is an independent Blue affiliate. Both plans require verifying coverage on their respective drug-lookup tools and confirming employer benefit design with HR. The honest answer is the same: employer opt-in is the deciding variable.

Medica Medicare plans cannot cover Wegovy for weight loss — that is a federal statutory exclusion on all Medicare Part D plans. Medica Medicare Advantage can cover Wegovy for the cardiovascular risk-reduction indication in members with established CVD who are overweight or obese, with prior authorization. The Medicare GLP-1 Bridge ($50/month, launching July 1, 2026) provides weight-loss access outside Part D for eligible beneficiaries.

Medica operates in Minnesota, Wisconsin, North Dakota, South Dakota, Iowa, and Nebraska. State matters primarily for Medicaid: each state has its own GLP-1 obesity coverage policy, and only 13 states covered GLP-1s for obesity in Medicaid as of January 2026. For commercial plans, the deciding factor is the same across all six states: whether your employer opted into the anti-obesity benefit. Verify Medicaid coverage on the state-specific Medica plan formulary.

No. Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management and cardiovascular risk reduction — it is not a diabetes drug. Attempting to route Wegovy through a diabetes drug benefit will result in denial. If you have type 2 diabetes and want semaglutide for that indication, Ozempic (semaglutide lower dose) is the diabetes-indicated product and is covered differently. Do not confuse Wegovy with Ozempic.

The Curex GLP-1 program

Whether or not Medica covers Wegovy, there's a path that skips insurance

Medica covers Wegovy for weight loss only where the employer opted in. For patients without that benefit, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.

Compounded semaglutide
from$49/mo
Weekly injection or oral tablet
Compounded tirzepatide
from$149/mo
Injection or oral tablet
  • Medication + free shipping
  • 24/7 provider access
  • Medical intake & prescription review
From $49/moNo insurance requiredNo prior auth
Build your personalized planPrescription required, subject to provider review.

Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Medica before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.

Weight care with Curex

Whether or not Medica covers Wegovy, there's a path that skips insurance

Build your personalized plan

Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.